Associated Papers
Emerging Evidence that ApoC-III Inhibitors Provide Novel Options to Reduce the Residual CVD.
Taskinen MR et al.
Current Atherosclerosis Reports, 2019
Loss-of-function mutations in APOC3, triglycerides, and coronary disease.
Crosby J et al.
The New England Journal of Medicine, 2014
Select a paper to view details